

# Publication design with incentives in mind

---

Ravi Jagadeesan  
Stanford

Davide Viviano  
Harvard

“Economists are quick to assume opportunistic behavior in almost every walk of life other than our own. Our empirical methods are based on assumptions of human behavior that would not pass muster in any of our models.” (Glaeser, 2006)

## Selective publication

- suppose an *editor* is deciding which findings to publish
  - published studies may inform the public about the state of the world
  - the public (*audience*) will take a decision after observing published studies
  - the editor wants to minimize the audience's loss

## Selective publication

- suppose an *editor* is deciding which findings to publish
  - published studies may inform the public about the state of the world
  - the public (*audience*) will take a decision after observing published studies
  - the editor wants to minimize the audience's loss
- if publication is costly (e.g., cognitive costs for the audience), optimal policy is to publish a result if and only if it is sufficiently “surprising”
  - Frankel and Kasy (2022)

## Selective publication

- suppose an *editor* is deciding which findings to publish
  - published studies may inform the public about the state of the world
  - the public (*audience*) will take a decision after observing published studies
  - the editor wants to minimize the audience's loss
- if publication is costly (e.g., cognitive costs for the audience), optimal policy is to publish a result if and only if it is sufficiently “surprising”
  - Frankel and Kasy (2022)
- but if *researchers* are interested in publishing, selective publication affects their incentives about **what** studies to conduct and **how** to implement them

## Selective publication

- suppose an *editor* is deciding which findings to publish
  - published studies may inform the public about the state of the world
  - the public (*audience*) will take a decision after observing published studies
  - the editor wants to minimize the audience's loss
- if publication is costly (e.g., cognitive costs for the audience), optimal policy is to publish a result if and only if it is sufficiently “surprising”
  - Frankel and Kasy (2022)
- but if *researchers* are interested in publishing, selective publication affects their incentives about **what** studies to conduct and **how** to implement them
  - e.g., may not run a costly large-scale experiment w/low chance of publishing
  - e.g., may manipulate results to increase chance of finding significant results

## This paper

taking researcher's incentives to publish into account, we ask:

1. which research designs should be incentivized more when?
2. what form (if any) of selective publication is optimal?

## This paper

taking researcher's incentives to publish into account, we ask:

1. which research designs should be incentivized more when?
2. what form (if any) of selective publication is optimal?

we formulate a model of optimal publication decisions that takes into account

- researcher's incentives about what studies to conduct (verifiable design)
- researcher's incentives to manipulate the findings (non verifiable design)

⇒ mechanism design problem with limited transfers



## This paper

taking researcher's incentives to publish into account, we ask:

1. which research designs should be incentivized more when?
2. what form (if any) of selective publication is optimal?

we formulate a model of optimal publication decisions that takes into account

- researcher's incentives about what studies to conduct (verifiable design)
- researcher's incentives to manipulate the findings (non verifiable design)

⇒ mechanism design problem with limited transfers

some takeaways:

1. optimal publication is biased towards studies that are cheaper for researchers to do
2. less surprising results, and manipulated results, are sometimes published
3. even if planner can enforce non manipulable designs, this can be sub-optimal

## Related literature

- economic analysis of statistics [Chassang et al. (2012); Tetenov (2016); Spiess (Forthcoming, 2025); Henry and Ottaviani (2019); Di Tillio et al. (2017); Viviano et al. (2025); Kasy and Spiess (2023)]
  - we study choosing between different study designs (and manipulation)
- modeling scientific approval and communication [Frankel and Kasy (2022); Andrews and Shapiro (2021); Glaeser (2006); Manski (2015)]
  - we provide model that incorporates researchers' incentives
- treatment effect literature with selection bias/external validity [e.g. Meager (2019); Allcott (2015); Beets et al. (2020); Rosenzweig and Udry (2016)]
  - we study how these issues interact with researcher's incentives
- work on decision theory and hypothesis testing [e.g., Wald (1950); Storey (2003); Efron (2008); Manski and Tetenov (2016); Manski (2004); McCloskey and Michailat (Forthcoming, 2024)]
  - we provide an economic model with incentives for publication rules

## Model setup

## Model overview

- three agents: an editor, an audience, and a researcher
- state of the world  $\theta \sim \mathcal{N}(\mu, \eta^2)$ ; without loss  $\mu = 0$

## Model overview

- three agents: an editor, an audience, and a researcher
  - state of the world  $\theta \sim \mathcal{N}(\mu, \eta^2)$ ; without loss  $\mu = 0$
1. editor pre-commit to a publication rule  $p(\cdot)$
  2. researcher chooses study design  $\Delta$  (associated with bias and variance)
    - to maximize chance of publication, net of cost  $C_\Delta$  of executing  $\Delta$

## Model overview

- three agents: an editor, an audience, and a researcher
  - state of the world  $\theta \sim \mathcal{N}(\mu, \eta^2)$ ; without loss  $\mu = 0$
1. editor pre-commit to a publication rule  $p(\cdot)$
  2. researcher chooses study design  $\Delta$  (associated with bias and variance)
    - to maximize chance of publication, net of cost  $C_\Delta$  of executing  $\Delta$
  3. researcher reports results  $X(\Delta)$

## Model overview

- three agents: an editor, an audience, and a researcher
  - state of the world  $\theta \sim \mathcal{N}(\mu, \eta^2)$ ; without loss  $\mu = 0$
1. editor pre-commit to a publication rule  $p(\cdot)$
  2. researcher chooses study design  $\Delta$  (associated with bias and variance)
    - to maximize chance of publication, net of cost  $C_\Delta$  of executing  $\Delta$
  3. researcher reports results  $X(\Delta)$
  4. if published, audience action  $a^*(X)$  to minimize expected loss  $[(a - \theta)^2 | X]$

## Model overview

- three agents: an editor, an audience, and a researcher
  - state of the world  $\theta \sim \mathcal{N}(\mu, \eta^2)$ ; without loss  $\mu = 0$
1. editor pre-commit to a publication rule  $p(\cdot)$
  2. researcher chooses study design  $\Delta$  (associated with bias and variance)
    - to maximize chance of publication, net of cost  $C_\Delta$  of executing  $\Delta$
  3. researcher reports results  $X(\Delta)$
  4. if published, audience action  $a^*(X)$  to minimize expected loss  $[(a - \theta)^2 | X]$
- editor minimizes audience's loss net of cost  $c_A$  per publication




## Model: two cases


1. **verifiable**:  $p(\cdot)$  can depend on  $X$  and  $\Delta$ , researcher does not know  $\theta$ 
  - choosing betw/ experiments with different precisions:  $X(\Delta) \sim \mathcal{N}(\theta, S_{\Delta}^2)$
  - cost varies by design
2. **non verifiable**: researcher chooses  $\Delta$  as function of data and  $p(\cdot)$  only depends on  $X$ 
  - researcher can introduce bias in the study
  - consider (reputational) cost for data manipulation

**Verifiable design**

## Model: verifiable design




## Model: verifiable design



- researcher:  $\max_{\Delta} b\mathbb{E}_X[p(X, \Delta)] - C_{\Delta}$  [without loss  $b = 1$ ]


## Model: verifiable design



- researcher:  $\max_{\Delta} b\mathbb{E}_X[p(X, \Delta)] - C_{\Delta}$  [without loss  $b = 1$ ]
- editor's objective:

$$\mathcal{L}_{\Delta} = \mathbb{E} \left[ \underbrace{p(X, \Delta)(a^*(X) - \theta)^2}_{\text{publication}} \right]$$


## Model: verifiable design



- researcher:  $\max_{\Delta} b\mathbb{E}_X[p(X, \Delta)] - C_{\Delta}$  [without loss  $b = 1$ ]
- editor's objective:

$$\mathcal{L}_{\Delta} = \mathbb{E} \left[ \underbrace{p(X, \Delta)(a^*(X) - \theta)^2}_{\text{publication}} + \underbrace{(1 - p(X, \Delta))(\theta - \mu)^2}_{\text{status quo}} \right]$$

## Model: verifiable design



- researcher:  $\max_{\Delta} b\mathbb{E}_X[p(X, \Delta)] - C_{\Delta}$  [without loss  $b = 1$ ]
- editor's objective:

$$\mathcal{L}_{\Delta} = \mathbb{E} \left[ \underbrace{p(X, \Delta)(a^*(X) - \theta)^2}_{\text{publication}} + \underbrace{(1 - p(X, \Delta))(\theta - \mu)^2}_{\text{status quo}} + \underbrace{p(X, \Delta)c_A}_{\text{cost}} \right]$$

## Which cheap studies to publish? ( $C_O = 0$ )

if the editor is constrained to implement  $\Delta = O$  with  $C_O = 0$ ,

then optimal publication decision rules satisfy (Frankel and Kasy, 2022)

$$p(X, O) = \begin{cases} 1 & \text{if } |X| > X_O^* \\ 0 & \text{if } |X| < X_O^* \end{cases},$$

where

$$X_O^* = \frac{S_O^2 + \eta^2}{\eta^2} \sqrt{c_A}$$



## Which cheap studies to publish? ( $C_O = 0$ )

if the editor is constrained to implement  $\Delta = O$  with  $C_O = 0$ ,

then optimal publication decision rules satisfy (Frankel and Kasy, 2022)

$$p(X, O) = \begin{cases} 1 & \text{if } |X| > X_O^* \\ 0 & \text{if } |X| < X_O^* \end{cases},$$

where

$$X_O^* = \frac{S_O^2 + \eta^2}{\eta^2} \sqrt{c_A}$$

- intuition: publish results that move  $a$  enough to be worth paying  $c_A$

## Which expensive studies to publish? $C_E > 0$

if the editor is constrained to implement  $\Delta = E$  with  $C_E > 0$ ,  
then optimal publication decision rules satisfy

$$p(X, E) = \begin{cases} 1 & \text{if } |X| > X_E^* \\ 0 & \text{if } |X| < X_E^* \end{cases},$$

where

$$X_E^* = \min \left\{ \frac{S_E^2 + \eta^2}{\eta^2} \sqrt{c_A}, \right.$$

## Which expensive studies to publish? $C_E > 0$

if the editor is constrained to implement  $\Delta = E$  with  $C_E > 0$ ,  
then optimal publication decision rules satisfy

$$p(X, E) = \begin{cases} 1 & \text{if } |X| > X_E^* \\ 0 & \text{if } |X| < X_E^* \end{cases},$$

where

$$X_E^* = \min \left\{ \frac{S_E^2 + \eta^2}{\eta^2} \sqrt{c_A}, \quad \Phi^{-1}(1 - C_E/2) \sqrt{S_E^2 + \eta^2} \right\}$$

- intuition: need to make  $\mathbb{E}[p(X, E)]$  large enough to implement  $E$

## Which expensive studies to publish? $C_E > 0$

if the editor is constrained to implement  $\Delta = E$  with  $C_E > 0$ ,  
then optimal publication decision rules satisfy

$$p(X, E) = \begin{cases} 1 & \text{if } |X| > X_E^* \\ 0 & \text{if } |X| < X_E^* \end{cases},$$

where

$$X_E^* = \min \left\{ \frac{S_E^2 + \eta^2}{\eta^2} \sqrt{c_A}, \quad \Phi^{-1}(1 - C_E/2) \sqrt{S_E^2 + \eta^2} \right\}$$

- intuition: need to make  $\mathbb{E}[p(X, E)]$  large enough to implement  $E$
- relevant if the researcher's IR constraint binds for  $\Delta = E$

# Implications

- suppose two designs are available:
  - cheaper but less accurate study  $O$ , with  $C_O > 0$
  - more expensive but more accurate study  $E$ , with  $C_E > C_O$
  - Define  $\text{PostVar}(\Delta) = \mathbb{V}(\theta|X(\Delta))$  the posterior variance
- should the planner publish results from  $O$ ? or from  $E$  alone?

# Implications

- suppose two designs are available:
  - cheaper but less accurate study  $O$ , with  $C_O > 0$
  - more expensive but more accurate study  $E$ , with  $C_E > C_O$
  - Define  $\text{PostVar}(\Delta) = \mathbb{V}(\theta|X(\Delta))$  the posterior variance
- should the planner publish results from  $O$ ? or from  $E$  alone?

Prop If both  $C_E, C_O$  are sufficiently small (but non-zero), and  $S_E < S_O$  the editor prefers  $E$

# Implications

- suppose two designs are available:
  - cheaper but less accurate study  $O$ , with  $C_O > 0$
  - more expensive but more accurate study  $E$ , with  $C_E > C_O$
  - Define  $\text{PostVar}(\Delta) = \mathbb{V}(\theta|X(\Delta))$  the posterior variance
- should the planner publish results from  $O$ ? or from  $E$  alone?

Prop If both  $C_E, C_O$  are sufficiently small (but non-zero), and  $S_E < S_O$  the editor prefers  $E$

Prop for  $O$  entailing non-trivial costs (IR is binding for  $O$ ) planner prefers  $E$  over  $O$  iff

$$\text{PostVar}(O) - \text{PostVar}(E) \geq (C_E - C_O)c_A + O(\epsilon)$$

with  $\epsilon = (1 - C_O)^3$  (exact expressions in the paper)

# Implications

- suppose two designs are available:
  - cheaper but less accurate study  $O$ , with  $C_O > 0$
  - more expensive but more accurate study  $E$ , with  $C_E > C_O$
  - Define  $\text{PostVar}(\Delta) = \mathbb{V}(\theta|X(\Delta))$  the posterior variance
- should the planner publish results from  $O$ ? or from  $E$  alone?

Prop If both  $C_E, C_O$  are sufficiently small (but non-zero), and  $S_E < S_O$  the editor prefers  $E$

Prop for  $O$  entailing non-trivial costs (IR is binding for  $O$ ) planner prefers  $E$  over  $O$  iff


$$\text{PostVar}(O) - \text{PostVar}(E) \geq (C_E - C_O)c_A + O(\epsilon)$$

with  $\epsilon = (1 - C_O)^3$  (exact expressions in the paper)

$\Rightarrow$  larger attention cost shifts preference towards less expensive design due to supply effect




## Graphical illustration




**Non-verifiable design**

## Model: asymmetric info case




- suppose that researcher knows selects the design knowing  $\theta + \varepsilon$ 
  - here,  $\varepsilon \sim \mathcal{N}(0, S^2)$  is common sampling uncertainty (with  $S^2 = 1$  interpret  $X$  as t-stat)

## Model: asymmetric info case




- suppose that researcher knows selects the design knowing  $\theta + \varepsilon$ 
  - here,  $\varepsilon \sim \mathcal{N}(0, S^2)$  is common sampling uncertainty (with  $S^2 = 1$  interpret  $X$  as t-stat)
- nontrivial potential designs  $\Delta \in \mathbb{R}$  parameterized by bias  $\beta_{\Delta} \in \mathbb{R}$

## Model: asymmetric info case



- suppose that researcher knows selects the design knowing  $\theta + \varepsilon$ 
  - here,  $\varepsilon \sim \mathcal{N}(0, S^2)$  is common sampling uncertainty (with  $S^2 = 1$  interpret  $X$  as t-stat)
- nontrivial potential designs  $\Delta \in \mathbb{R}$  parameterized by bias  $\beta_{\Delta} \in \mathbb{R}$
- researcher chooses  $\Delta$  to max  $p(X) - C_{\Delta}$ , where  $C_{\Delta} = c_M |\beta_{\Delta}|$  [fixed costs in the paper]

## Model: asymmetric info case



- suppose that researcher knows selects the design knowing  $\theta + \varepsilon$ 
  - here,  $\varepsilon \sim \mathcal{N}(0, S^2)$  is common sampling uncertainty (with  $S^2 = 1$  interpret  $X$  as t-stat)
- nontrivial potential designs  $\Delta \in \mathbb{R}$  parameterized by bias  $\beta_{\Delta} \in \mathbb{R}$
- researcher chooses  $\Delta$  to max  $p(X) - C_{\Delta}$ , where  $C_{\Delta} = c_M |\beta_{\Delta}|$  [fixed costs in the paper]
- audience forms posterior under naive assumption of no bias  $\beta_{\Delta}$

## Optimal publication rule

Optimal publication rule minimizes audience's loss accounting for researcher's best action.

Thm: optimal publication rule takes the form

$$p(X) = \begin{cases} 0 & \text{if } |X| \leq X^* - \frac{1}{c_M} \\ 1 - c_M(X^* - |X|) & \text{if } X^* - \frac{1}{c_M} < |X| < X^* \\ 1 & \text{otherwise} \end{cases}$$

where  $X^* > t^*$ , where  $t^*$  is optimal threshold with no manipulation

## Optimal publication rule

Optimal publication rule minimizes audience's loss accounting for researcher's best action.

Thm: optimal publication rule takes the form

$$p(X) = \begin{cases} 0 & \text{if } |X| \leq X^* - \frac{1}{c_M} \\ 1 - c_M(X^* - |X|) & \text{if } X^* - \frac{1}{c_M} < |X| < X^* \\ 1 & \text{otherwise} \end{cases}$$

where  $X^* > t^*$ , where  $t^*$  is optimal threshold with no manipulation




- publication mitigates manipulation, but does not eliminate it
- it raises the threshold for guaranteed publication
- it randomizes publication (just) below the threshold
- it publishes some results with  $|X| < t^*$



# Implications

Publication rule	Testable observation	Published results	Manipulation
Optimal cutoff rule ignoring manipulation	Large bunching	Only results with $ X  \geq t^*$	Large
Add randomization below cutoff	No bunching	Many results with $ X  < t^*$	None
Optimal rule (Randomize + raise cutoff)	Some bunching	Some results with $ X  < t^*$	Some

# Implications



## **An empirical illustration to medical studies**

## Application to medical publications

- Pub/ in top medical journals signal for marketing and credibility (Modi et al., 2023)
- However, clinical trials are often expensive and costs are burnt privately
  - ⇒ Moved researchers and FDA to a debate on the use of synthetic or external control groups
  - Q: publication rule in the absence of a pre-specified (manipulable) experiment?

## Application to medical publications

- Pub/ in top medical journals signal for marketing and credibility (Modi et al., 2023)
- However, clinical trials are often expensive and costs are burnt privately
  - ⇒ Moved researchers and FDA to a debate on the use of synthetic or external control groups
  - Q: publication rule in the absence of a pre-specified (manipulable) experiment?
- Head et al. (2015) collect  $\sim 800,000$   $p$ -values from PubMed for medical and pharmaceutical journals. We invert  $X_i = \Phi^{-1}(1 - p_i/2)$  to obtain t-stat
- we model  $X_i = \theta_i + \beta_i + \varepsilon_i$ , with  $\varepsilon_i \sim \mathcal{N}(0, 1)$  and  $\theta_i \sim \mathcal{N}(0, \eta^2)$   
[zero mean consistent with existing meta-analysis (Bartoš et al., 2023)]

# Application to medical publications

- Pub/ in top medical journals signal for marketing and credibility (Modi et al., 2023)
- However, clinical trials are often expensive and costs are burnt privately
  - ⇒ Moved researchers and FDA to a debate on the use of synthetic or external control groups
  - Q: publication rule in the absence of a pre-specified (manipulable) experiment?
- Head et al. (2015) collect  $\sim 800,000$   $p$ -values from PubMed for medical and pharmaceutical journals. We invert  $X_i = \Phi^{-1}(1 - p_i/2)$  to obtain t-stat
- we model  $X_i = \theta_i + \beta_i + \varepsilon_i$ , with  $\varepsilon_i \sim \mathcal{N}(0, 1)$  and  $\theta_i \sim \mathcal{N}(0, \eta^2)$   
[zero mean consistent with existing meta-analysis (Bartoš et al., 2023)]
- Some remarks:
  - 36% of study never published (Vorland et al., 2024); we will assume all these are non-significant for simplicity – also consistent with Showell et al. (2024)
  - 27% of studies in PubMed 2002-15 are pre-specified exp/ (Lamberink et al., 2022).

## Application to medical publications

- Pub/ in top medical journals signal for marketing and credibility (Modi et al., 2023)
- However, clinical trials are often expensive and costs are burnt privately
  - ⇒ Moved researchers and FDA to a debate on the use of synthetic or external control groups
  - Q: publication rule in the absence of a pre-specified (manipulable) experiment?
- Head et al. (2015) collect  $\sim 800,000$   $p$ -values from PubMed for medical and pharmaceutical journals. We invert  $X_i = \Phi^{-1}(1 - p_i/2)$  to obtain t-stat
- we model  $X_i = \theta_i + \beta_i + \varepsilon_i$ , with  $\varepsilon_i \sim \mathcal{N}(0, 1)$  and  $\theta_i \sim \mathcal{N}(0, \eta^2)$   
[zero mean consistent with existing meta-analysis (Bartoš et al., 2023)]
- Some remarks:
  - 36% of study never published (Vorland et al., 2024); we will assume all these are non-significant for simplicity – also consistent with Showell et al. (2024)
  - 27% of studies in PubMed 2002-15 are pre-specified exp/ (Lamberink et al., 2022).
- task: calibrate  $(\eta^2, c_A, c_M)$  [sunk fixed costs, can be relaxed]

- For publication rules  $1\{|X| \geq 1.96\}$ , we should observe bunching at 1.96. Therefore take

$$\Phi(1.96) - \Phi\left(1.96 - \frac{1}{c_M}\right) = \underbrace{s_{1.96}}_{\text{share t-stat around 1.96}} \times \underbrace{(1 - 0.36)}_{\text{Share published}} \times \underbrace{\frac{1}{1 - 0.27}}_{\text{Share manipulable}}$$



- For publication rules  $1\{|X| \geq 1.96\}$ , we should observe bunching at 1.96. Therefore take

$$\Phi(1.96) - \Phi\left(1.96 - \frac{1}{c_M}\right) = \underbrace{s_{1.96}}_{\text{share t-stat around 1.96}} \times \underbrace{(1 - 0.36)}_{\text{Share published}} \times \underbrace{\frac{1}{1 - 0.27}}_{\text{Share manipulable}}$$




- For  $\eta^2$  use 95<sup>th</sup> quantile (adjusting for pub bias) equal to 3.43 ( $\gg 1.96$ )  $\Rightarrow \eta^2 = 1.94$ .
- For  $c_A$ , choose  $t^* = 1.96 \Rightarrow \sqrt{c_A} \frac{1+\eta^2}{\eta^2} = 1.96$ , the standard 5%-critical value

- For publication rules  $1\{|X| \geq 1.96\}$ , we should observe bunching at 1.96. Therefore take

$$\Phi(1.96) - \Phi\left(1.96 - \frac{1}{c_M}\right) = \underbrace{s_{1.96}}_{\text{share t-stat around 1.96}} \times \underbrace{(1 - 0.36)}_{\text{Share published}} \times \underbrace{\frac{1}{1 - 0.27}}_{\text{Share manipulable}}$$

- For  $\eta^2$  use 95<sup>th</sup> quantile (adjusting for pub bias) equal to 3.43 ( $\gg 1.96$ )  $\Rightarrow \eta^2 = 1.94$ .
- For  $c_A$ , choose  $t^* = 1.96 \Rightarrow \sqrt{c_A} \frac{1 + \eta^2}{\eta^2} = 1.96$ , the standard 5%-critical value
- In the paper, same analysis also with  $t^* = 2.56$ .

## Distribution of $X$ in equilibrium



## Optimal rule vs standard threshold

Publication rule	% Published	Within published findings		
		% $ X  < 1.96$	% Manipulated	Average Bias $ \beta $
$t$ -test rule $1\{ X  \geq 1.96\}$ (without manipulation)	25%	0%	—	—
$t$ -test rule $1\{ X  \geq 1.96\}$ (with manipulation)	58%	0%	56%	0.31
Optimal rule ( $X^* = 2.64$ )	25%	5%	45%	0.11

## Choosing an experiment or observational study?

- recent debates for FDA for use of external or “matched” controls vs pre-specified experiments ([Food and Drug Administration, 2023](#))  $\Rightarrow$  lower cost but manipulability

*[...] In an externally controlled trial, outcomes in participants receiving the test treatment according to a protocol are compared to outcomes in a group of people external to the trial who had not received the same treatment. The external control arm can be a group of people, treated or untreated, from an earlier time (historical control), or it can be a group of people, treated or untreated, during the same time period (concurrent control) but in another setting.*



## Choosing an experiment or observational study?

- recent debates for FDA for use of external or “matched” controls vs pre-specified experiments ([Food and Drug Administration, 2023](#))  $\Rightarrow$  lower cost but manipulability

*[...] In an externally controlled trial, outcomes in participants receiving the test treatment according to a protocol are compared to outcomes in a group of people external to the trial who had not received the same treatment. The external control arm can be a group of people, treated or untreated, from an earlier time (historical control), or it can be a group of people, treated or untreated, during the same time period (concurrent control) but in another setting.*

- takeaways:
  - in some therapeutic areas obs studies may be preferred when exp cost is high
  - but only true if adopt different publication rules for obs studies and exp/

# Calibration with our model



## Conclusions



# Conclusions

- the design of scientific communication shapes research process
  - with a verifiable design planner's preference must depend on research and attention costs
  - with non-verifiable design, optimal publication rule
    - publishes some results that would not be published in absence of manipulation
    - publishes some manipulated findings
    - increases the threshold for guaranteed publication

# Conclusions

- the design of scientific communication shapes research process
  - with a verifiable design planner's preference must depend on research and attention costs
  - with non-verifiable design, optimal publication rule
    - publishes some results that would not be published in absence of manipulation
    - publishes some manipulated findings
    - increases the threshold for guaranteed publication
  - application to medical study illustrates that
    - incentives for manipulation can significantly change standard  $t$ -test rules
    - choosing synthetic control groups requires different publication standards

# Conclusions

- the design of scientific communication shapes research process
  - with a verifiable design planner's preference must depend on research and attention costs
  - with non-verifiable design, optimal publication rule
    - publishes some results that would not be published in absence of manipulation
    - publishes some manipulated findings
    - increases the threshold for guaranteed publication
  - application to medical study illustrates that
    - incentives for manipulation can significantly change standard  $t$ -test rules
    - choosing synthetic control groups requires different publication standards

## Open questions:

- more complex decisions of planner and researcher
- general models of manipulation
- application to other forms of decisions/loss functions
- ...

**Thanks very much, questions?**

# References

- Allcott, H., 2015. Site selection bias in program evaluation. *Quarterly Journal of Economics* 130, 1117–1165.
- Andrews, I., Shapiro, J.M., 2021. A model of scientific communication. *Econometrica* 89, 2117–2142.
- Bartoš, F., Otte, W.M., Gronau, Q.F., Timmers, B., Ly, A., Wagenmakers, E.J., 2023. Empirical prior distributions for Bayesian meta-analyses of binary and time to event outcomes. *arXiv preprint arXiv:2306.11468* .
- Beets, M.W., Weaver, R.G., Ioannidis, J.P., Geraci, M., Brazendale, K., Decker, L., Okely, A.D., Lubans, D., Van Sluijs, E., Jago, R., et al., 2020. Identification and evaluation of risk of generalizability biases in pilot versus efficacy/effectiveness trials: a systematic review and meta-analysis. *International Journal of Behavioral Nutrition and Physical Activity* 17, 1–20.
- Chassang, S., Padro I Miquel, G., Snowberg, E., 2012. Selective trials: A principal-agent approach to randomized controlled experiments. *American Economic Review* 102, 1279–1309. URL: <https://www.aeaweb.org/articles?id=10.1257/aer.102.4.1279>, doi:10.1257/aer.102.4.1279.

- Di Tillio, A., Ottaviani, M., Sørensen, P.N., 2017. Persuasion bias in science: Can economics help? *Economic Journal* 127, F266–F304.
- Efron, B., 2008. Simultaneous inference: when should hypothesis testing problems be combined? *Annals of Applied Statistics* 2, 197–223.
- Food and Drug Administration, 2023. Considerations for the design and conduct of externally controlled trials for drug and biological products. Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products>.
- Frankel, A., Kasy, M., 2022. Which findings should be published? *American Economic Journal: Microeconomics* 14, 1–38.
- Glaeser, E.L., 2006. Researcher incentives and empirical methods. Working paper, National Bureau of Economic Research.
- Head, M.L., Holman, L., Lanfear, R., Kahn, A.T., Jennions, M.D., 2015. The extent and consequences of p-hacking in science. *PLoS Biology* 13, e1002106.
- Henry, E., Ottaviani, M., 2019. Research and the approval process: the organization of persuasion. *American Economic Review* 109, 911–55.

- Kasy, M., Spiess, J., 2023. Optimal pre-analysis plans: Statistical decisions subject to implementability  
Working paper, University of Oxford and Stanford University.
- Lamberink, H.J., Vinkers, C.H., Lancee, M., Damen, J.A., Bouter, L.M., Otte, W.M., Tijdink, J.K., 2022.  
Clinical trial registration patterns and changes in primary outcomes of randomized clinical trials from 2002 to 2017. *JAMA Internal Medicine* 182, 779–782.
- Manski, C., 2004. Statistical treatment rules for heterogeneous populations. *Econometrica* 72, 1221–1246.
- Manski, C.F., 2015. Randomizing regulatory approval for adaptive diversification and deterrence. *The Journal of Legal Studies* 44, S367–S385.
- Manski, C.F., Tetenov, A., 2016. Sufficient trial size to inform clinical practice. *Proceedings of the National Academy of Sciences* 113, 10518–10523.
- McCloskey, A., Michailat, P., Forthcoming, 2024. Critical values robust to p-hacking. *Review of Economics and Statistics* .
- Meager, R., 2019. Understanding the average impact of microcredit expansions: A Bayesian hierarchical analysis of seven randomized experiments. *American Economic Journal: Applied Economics* 11, 57–91.

- Modi, N.D., Kichenadasse, G., Hoffmann, T.C., Haseloff, M., Logan, J.M., Veroniki, A.A., Venchiarutti, R.L., Smit, A.K., Tuffaha, H., Jayasekara, H., et al., 2023. A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies. *BMC Medicine* 21, 400.
- Rosenzweig, M., Udry, C., 2016. External validity in a stochastic world. Technical Report. National bureau of economic research.
- Showell, M.G., Cole, S., Clarke, M.J., DeVito, N.J., Farquhar, C., Jordan, V., 2024. Time to publication for results of clinical trials. *Cochrane Database of Systematic Reviews* .
- Spiess, J., Forthcoming, 2025. Optimal estimation when researcher and social preferences are misaligned. *Econometrica* .
- Storey, J.D., 2003. The positive false discovery rate: a Bayesian interpretation and the q-value. *The Annals of Statistics* 31, 2013–2035.
- Tetenov, A., 2016. An economic theory of statistical testing. Working Paper, University of Bristol.
- Viviano, D., Wuthrich, K., Niehaus, P., 2025. A model of multiple hypothesis testing arXiv:2104.13367.
- Vorland, C.J., Brown, A.W., Kilicoglu, H., Ying, X., Mayo-Wilson, E., 2024. Publication of results of registered trials with published study protocols, 2011-2022. *JAMA Network Open* 7, e2350688–e2350688.
- Wald, A., 1950. *Statistical Decision Functions*. Wiley.